Investor Presentaiton

Investor Presentation First six months of 2018 Slide 43 Novo Nordisk increased market share in long-acting insulin and sustained leadership in fast-acting and premix insulin Long-acting insulin¹ volume market share across regions Novo Nordisk Fast-acting insulin² volume market share across regions North America Operations Region China Premix insulin³ volume market share across regions Region AAMEO Region Latin America 80% 70% 60% 50% 40% 30% 20% 10% 0% May 2013 80% 70% 60% 50% 40% 30% 20% 10% 0% May 2018 May 2013 Region Europe Region Japan & Korea 80% 70% 60% 50% 40% 30% 20% 10% 0% May May 2018 2013 May 2018 1 Long-acting insulin comprises: TresibaⓇ, Levemir®, XultophyⓇ and Insulatard® (basal human insulin). Please note that not all products are launched in all markets 2 Short-acting insulin includes: Fiasp®, NovoLogⓇ and ActrapidⓇ (bolus human insulin). Please note that not all products are launched in all markets 3 Premix insulin includes: RyzodegⓇ, NovoMixⓇ and Mixtard® 30 (premix human insulin). Please note that not all products are launched in all markets changing diabetes® novo nordisk

View entire presentation